Retina · Evidence-based overview

Neovascular age-related macular degeneration (nAMD)

Diagnosis, activity assessment, and individualized anti-VEGF treatment—with exam- and practice-relevant limits of the evidence.

English12 minutesMedically and editorially reviewedReview: 24 Sep 2026 · 21:19 CEST
Scope: Professional educational information. Drug selection, dosing, and intervals must be adapted to authorization, product information, findings, and the individual patient.

For active nAMD, prompt intravitreal anti-VEGF therapy is standard care. Management should not be based on one OCT slice alone, but on visual function, serial OCT, hemorrhage, and the overall clinical findings.[1]

1. Definition and clinical relevance

nAMD is a late form of AMD characterized by macular neovascularization (MNV). Exudation, hemorrhage, fibrosis, and atrophy can cause rapid and permanent central vision loss. Early confirmation of the diagnosis and consistent treatment improve the chance of preserving visual function.[1] [2]

This page covers only the neovascular form. Early/intermediate AMD, AREDS2, geographic atrophy, iRORA/cRORA, complement inhibitors, and photobiomodulation belong in separate chapters.

2. Classification of macular neovascularization

TypeAnatomic locationTypical cluesImportant limitation
Type 1Below the RPEIrregular RPE elevation, sub-RPE material; SRF may be present.A fibrovascular PED is common but not mandatory.
Type 2Subretinal, above the RPESubretinal hyperreflective material, often marked exudation.Calling it “more aggressive” does not provide reliable individual prognostication.
Type 3Intraretinal origin/retinal proliferationFocal hyperreflective lesion, IRF, often hemorrhage; bilateral predisposition is common.Avoid rigid claims about location, direction of growth, or long-term prognosis.
PCV / aneurysmal type 1 MNVSub-RPE with aneurysmal lesionsPeaked/notched PED, subretinal hemorrhage, branching vascular network.OCT signs are suggestive; ICGA remains particularly important for confident phenotyping.[9]

3. Symptoms and urgency

  • New metamorphopsia, central visual loss, or a positive/negative central scotoma.
  • New macular hemorrhage or acute central visual deterioration requires prompt ophthalmic assessment.
  • A normal Amsler test does not exclude activity and cannot replace examination or OCT.

4. Diagnostic assessment

Initial assessment includes best-corrected visual acuity, dilated fundus examination, and macular OCT. The German professional societies also recommend fluorescein angiography for the initial diagnosis; OCTA, FAF, and ICGA are added according to the clinical question and phenotype.[1]

ModalityMain valuePitfall
SD-OCTIRF, SRF, sub-RPE fluid, SHRM, PED, atrophy/fibrosis; follow-up.A dry OCT alone does not prove durable inactivity.
FALeakage, lesion extent, differential diagnosis.Hemorrhage and blocked fluorescence can limit interpretation.
OCTANon-invasive visualization of the vascular network.Flow artifacts; exudation and leakage are not shown directly.
ICGAPCV/aneurysmal lesions and choroidal vascular structures.Not required at every routine follow-up.

5. Activity and treatment decisions

Relevant activity signs include new or increasing IRF/SRF or sub-RPE fluid, new hemorrhage, meaningful visual loss without a better explanation, and angiographic lesion activity. Findings must be integrated and compared over time.[1]

Interpret fluid correctly

  • IRF: usually a clinically relevant activity sign and an adverse prognostic marker; consider mimics such as degenerative cysts.
  • SRF: a small stable residual amount may be tolerated within a controlled treat-and-extend regimen.
  • Important: FLUID does not justify observation without treatment. The tolerant arm continued ranibizumab; SRF up to 200 µm at the foveal center was allowed within the trial algorithm.[4]

6. Anti-VEGF treatment

Anti-VEGF is the standard treatment for active nAMD. Options authorized in Germany/the EU include—subject to current product information—ranibizumab, aflibercept, brolucizumab, and faricimab; ophthalmic bevacizumab use is off-label.[1] [10]

AgentClassInterval evidenceKey considerations
RanibizumabAnti-VEGF-AFixed, PRN, and treat-and-extend regimens are possible.FLUID studied ranibizumab; do not transfer its result uncritically to other regimens.
Aflibercept 2 mgVEGF trapFixed and activity-guided regimens.Follow the agent- and patient-specific initiation schedule.
Aflibercept 8 mgHigh-dose afliberceptPULSAR tested 12- or 16-week intervals after three monthly doses versus 2 mg every 8 weeks.[7] [8]Longer study intervals are not guaranteed for every patient; activity criteria remain decisive.
FaricimabVEGF-A/Ang-2TENAYA/LUCERNE showed non-inferiority to aflibercept 2 mg with individualized intervals up to 16 weeks; visual gains were maintained through year 2.[5] [6]Trial populations and protocols differ from routine care.
BrolucizumabAnti-VEGF-ALonger intervals may be possible in suitable eyes.Pay particular attention to intraocular inflammation, retinal vasculitis, and vascular occlusion; current product information is decisive.[10]
BevacizumabAnti-VEGF-A; ophthalmic off-label useEfficacy is supported by randomized comparative evidence.Address off-label consent, compounding, and local requirements.

Treatment strategies

  • Fixed dosing: predictable but may expose some patients to unnecessary injections.
  • PRN: treatment for activity after initiation; requires close monitoring and risks undertreatment if follow-up is inadequate.
  • Treat-and-extend: treatment at every visit, extending the interval when inactive and shortening it when active. The exact algorithm depends on the agent, findings, and patient.[1]

7. Inadequate response

Before switching agents, reassess the diagnosis, adherence, injection intervals, chronic structural changes, and differential diagnoses. Persistent fluid does not automatically mean tachyphylaxis. Ask:

  • Is this true exudative activity or a degenerative cyst?
  • Was PCV, type 3 MNV, or another diagnosis missed?
  • Is fibrosis or atrophy limiting function despite anatomic control?
  • Is the interval longer than the individual duration of effect?

8. PCV: plan treatment by phenotype

Anti-VEGF monotherapy is effective. In EVEREST II, ranibizumab plus verteporfin PDT produced greater visual gain, more complete polyp regression, and fewer treatments over 24 months than ranibizumab alone. The population was predominantly Asian, which limits automatic extrapolation to every PCV phenotype.[9]

9. Exam essentials

Which findings determine activity?

OCT fluid, new hemorrhage, functional course, and—when needed—angiographic activity are assessed together. No single finding replaces longitudinal assessment.

Can small amounts of SRF be observed?

A small stable amount may be tolerated while continuing a treat-and-extend regimen. FLUID did not test untreated observation.

Is PED mandatory for type 1 MNV?

No. Irregular RPE elevation or fibrovascular PED is common but not mandatory in every type 1 MNV.

When should PCV be suspected?

Consider it with hemorrhagic disease, serosanguineous PED, peaked/notched PED, or inadequate response to standard treatment. ICGA supports confident phenotyping.

Guidelines, regulatory sources, and primary studies

Last medical and editorial review: 24 Sep 2026, 21:19 CEST. Links last checked 24 Sep 2026.

  1. German professional societies · Statement · 2022
    DOG/BVA/RG: Anti-VEGF therapy for neovascular AMD
    Practice-oriented German guidance. Limitation: published before aflibercept 8 mg and newer long-term data.
  2. Guideline · AAO Preferred Practice Pattern · 2024
    American Academy of Ophthalmology: Age-Related Macular Degeneration PPP
    Evidence-based US guidance; authorization and care context differ from Germany.
  3. German guideline · 2023
    DOG/BVA: Age-related macular degeneration
    Broad AMD guidance; consult current product information for individual drugs.
  4. Randomized non-inferiority trial · 24 months · 2019
    FLUID: Tolerating Subretinal Fluid in Treat-and-Extend Ranibizumab
    Supports an SRF-tolerant treatment strategy, not withdrawal of anti-VEGF. Protocol-specific threshold in a single trial.
  5. Two randomized phase III trials · 2022
    TENAYA/LUCERNE: Faricimab up to Q16W versus aflibercept Q8W
    Non-inferiority data in treatment-naive nAMD; industry funded.
  6. Phase III long-term data · 2 years · 2024
    TENAYA/LUCERNE: Two-Year Results
    Functional outcomes were maintained under protocol-directed treat-and-extend; routine adherence may differ.
  7. Randomized phase III trial · 48 weeks · 2024
    PULSAR: Aflibercept 8 mg versus 2 mg
    Non-inferiority data with predefined extended intervals; industry funded.
  8. Phase III long-term data · 96 weeks · 2026
    PULSAR: Aflibercept 8 mg – Week 96 Results
    Supports longer intervals in suitable patients; individual activity remains limiting.
  9. Randomized clinical trial · PCV · 24 months · 2020
    EVEREST II: Ranibizumab with or without verteporfin PDT
    Direct PCV evidence; predominantly Asian population limits generalizability.
  10. Regulatory primary sources · EMA · continuously updated
    Eylea · Vabysmo · Lucentis · Beovu
    For authorization and safety; current national product information remains decisive.

EyeWiki and lecture videos were not used as sole evidence. Claims were traced to guidelines, regulatory sources, and primary studies.